Long-term outcome of proton therapy and carbon-ion therapy for large (T2a-T2bN0M0) non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 6, 2013, Pages 726-735

  Iwata, Hiromitsu ^a,b,c   Demizu, Yusuke ^b   Fujii, Osamu ^b   Terashima, Kazuki ^b   Mima, Masayuki ^b   Niwa, Yasue ^b   Hashimoto, Naoki ^b   Akagi, Takashi ^b   Sasaki, Ryohei ^d   Hishikawa, Yoshio ^b   Abe, Mitsuyuki ^b   Shibamoto, Yuta ^a   Murakami, Masao ^e   Fuwa, Nobukazu ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b HYOGO ION BEAM MEDICAL CENTER   (Japan)

^c Nagoya City University West Medical Center   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

7th edition International Union Against Cancer; Carbon ion therapy; Metastasis classification; Node; Non small cell lung cancer; Proton therapy; T2a 2b; Tumor

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HYPERBARIC OXYGEN; ION THERAPY; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTON THERAPY; RADIATION DERMATITIS; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RIB FRACTURE; SKIN ULCER;

EID: 84879498329     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318288ab02     Document Type: Article

References (38)

1. Durand RE. Cell cycle kinetics in an in vitro tumor model. Cell Tissue Kinet 1976;9:403-412.
2. Shibamoto Y, Yukawa Y, Tsutsui K, Takahashi M, Abe M. Variation in the hypoxic fraction among mouse tumors of different types, sizes, and sites. Jpn J Cancer Res 1986;77:908-915. (Pubitemid 16006786)
3. Sugahara S, Oshiro Y, Nakayama H, et al. Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010;76:460-466.
4. Tsujii H, Kamada T. A review of update clinical results of carbon ion radiotherapy. Jpn J Clin Oncol 2012;42:670-685.
5. Goldstraw P, Groome PA. UICC International Union Against Cancer. Lung and pleural tumors. In: Sobin LH, Gospodarowicz MK, Wittekind C (Ed). TNM Classification of Malignant Tumors, 7th Ed. Oxford: Wiley- Blackwell, 2009. Pp.138-150.
6. Goldstraw P, Crowley J, Chansky K, et al.; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714. (Pubitemid 47357522)
7. Rami-Porta R, Ball D, Crowley J, et al.; International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2:593-602. (Pubitemid 47171780)
8. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Stereotactic body radiotherapy for central lung tumors. J Thorac Oncol 2012;7:1394-1399.
9. Guckenberger M, Kestin LL, Hope AJ, et al. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer? J Thorac Oncol 2012;7:542-551.
10. Dunlap NE, Larner JM, Read PW, et al. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). J Thorac Cardiovasc Surg 2010;140:583-589.
11. Koto M, Takai Y, Ogawa Y, et al. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 2007;85:429-434. (Pubitemid 350213143)
12. Guckenberger M, Baier K, Polat B, et al. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol 2010;97:65-70.
13. Iwata H, Murakami M, Demizu Y, et al. High-dose proton therapy and carbon-ion therapy for stage I nonsmall cell lung cancer. Cancer 2010;116:2476-2485.
14. Roelofs E, Engelsman M, Rasch C, et al.; ROCOCO Consortium. Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol 2012;7:165-176.
15. Hishikawa Y, Oda Y, Mayahara H, et al. Status of the clinical work at Hyogo. Radiother Oncol 2004;73 Suppl 2:S38-S40. (Pubitemid 41219111)
16. Minohara S, Kanai T, Endo M, Noda K, Kanazawa M. Respiratory gated irradiation system for heavy-ion radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:1097-1103. (Pubitemid 30345611)
17. Shibamoto Y, Hashizume C, Baba F, et al. Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer: a multicenter study. Cancer 2012;118:2078-2084.
18. Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2(7 Suppl 3):S94-100. (Pubitemid 47183602)
19. Nakayama H, Sugahara S, Tokita M, et al. Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the university of tsukuba. Int J Radiat Oncol Biol Phys 2010;78:467-471.
20. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009;27:3290-3296.
21. Guckenberger M, Wulf J, Mueller G, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 2009;74:47-54.
22. van der Voort van Zyp NC, Prévost JB, Hoogeman MS, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol 2009;91:296-300.
23. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-1076.
24. Suit H, DeLaney T, Goldberg S, et al. Proton vs carbon ion beams in the definitive radiation treatment of cancer patients. Radiother Oncol 2010;95:3-22.
25. Shibamoto Y, Ike O, Mizuno H, Fukuse T, Hitomi S, Takahashi M. Proliferative activity and micronucleus frequency after radiation of lung cancer cells as assessed by the cytokinesis-block method and their relationship to clinical outcome. Clin Cancer Res 1998;4:677-682. (Pubitemid 28193568)
26. Asai K, Shioyama Y, Nakamura K, et al. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy: risk factors and dose-volume relationship. Int J Radiat Oncol Biol Phys 2012;84:768-773.
27. Nambu A, Onishi H, Aoki S, et al. Rib fracture after stereotactic radiotherapy on follow-up thin-section computed tomography in 177 primary lung cancer patients. Radiat Oncol 2011;6:137.
28. Furusawa Y, Fukutsu K, Aoki M, et al. Inactivation of aerobic and hypoxic cells from three different cell lines by accelerated (3)He-, (12)C- and (20) Ne-ion beams. Radiat Res 2000;154:485-496.
29. Grevillot L, Bertrand D, Dessy F, Freud N, Sarrut D. A Monte Carlo pencil beam scanning model for proton treatment plan simulation using GATE/GEANT4. Phys Med Biol 2011;56:5203-5219.
30. Mori S, Kanematsu N, Asakura H, et al. Four-dimensional lung treatment planning in layer-stacking carbon ion beam treatment: comparison of layer-stacking and conventional ungated/gated irradiation. Int J Radiat Oncol Biol Phys 2011;80:597-607.
31. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-5051.
32. Winton T, Livingston R, Johnson D, et al.; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597. (Pubitemid 41007845)
33. Cai XW, Xu LY, Wang L, et al. Comparative survival in patients with postresection recurrent versus newly diagnosed non-small-cell lung cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2010;76:1100-1105.
34. Manabe Y, Shibamoto Y, Baba F, et al. Radiotherapy for hilar or mediastinal lymph node metastases after definitive treatment with stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer. Pract Radiat Oncol 2012;2:e137-143.
35. Seco J, Panahandeh HR, Westover K, Adams J, Willers H. Treatment of non-small cell lung cancer patients with proton beam-based stereotactic body radiotherapy: dosimetric comparison with photon plans highlights importance of range uncertainty. Int J Radiat Oncol Biol Phys 2012;83:354-361.
36. Kadoya N, Obata Y, Kato T, et al. Dose-volume comparison of proton radiotherapy and stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;79:1225-1231.
37. Kanematsu N, Akagi T, Takatani Y, Yonai S, Sakamoto H, Yamashita H. Extended collimator model for pencil-beam dose calculation in proton radiotherapy. Phys Med Biol 2006;51:4807-4817. (Pubitemid 44429845)
38. Kanematsu N. Modeling of beam customization devices in the pencilbeam splitting algorithm for heavy charged particle radiotherapy. Phys Med Biol 2011;56:1361-1371.